Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis

Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 215(2020) vom: 15. Juni, Seite 108451
1. Verfasser: Takatani, Ayuko (VerfasserIn)
Weitere Verfasser: Koga, Tomohiro, Fujita, Yuya, Fukui, Shoichi, Endo, Yushiro, Shimizu, Toshimasa, Kawakami, Atsushi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Case Reports Letter Research Support, Non-U.S. Gov't Anti-MDA5 antibody Dermatomyositis IL-15 Interstitial lung disease Tofacitinib Autoantibodies Piperidines mehr... Protein Kinase Inhibitors Pyrimidines tofacitinib 87LA6FU830 IFIH1 protein, human EC 3.6.1.- Interferon-Induced Helicase, IFIH1 EC 3.6.4.13
LEADER 01000naa a22002652 4500
001 NLM309441250
003 DE-627
005 20231225133923.0
007 cr uuu---uuuuu
008 231225s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2020.108451  |2 doi 
028 5 2 |a pubmed24n1031.xml 
035 |a (DE-627)NLM309441250 
035 |a (NLM)32360518 
035 |a (PII)S1521-6616(20)30281-3 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Takatani, Ayuko  |e verfasserin  |4 aut 
245 1 0 |a Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 29.01.2021 
500 |a Date Revised 29.01.2021 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
650 4 |a Case Reports 
650 4 |a Letter 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Anti-MDA5 antibody 
650 4 |a Dermatomyositis 
650 4 |a IL-15 
650 4 |a Interstitial lung disease 
650 4 |a Tofacitinib 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a Piperidines  |2 NLM 
650 7 |a Protein Kinase Inhibitors  |2 NLM 
650 7 |a Pyrimidines  |2 NLM 
650 7 |a tofacitinib  |2 NLM 
650 7 |a 87LA6FU830  |2 NLM 
650 7 |a IFIH1 protein, human  |2 NLM 
650 7 |a EC 3.6.1.-  |2 NLM 
650 7 |a Interferon-Induced Helicase, IFIH1  |2 NLM 
650 7 |a EC 3.6.4.13  |2 NLM 
700 1 |a Koga, Tomohiro  |e verfasserin  |4 aut 
700 1 |a Fujita, Yuya  |e verfasserin  |4 aut 
700 1 |a Fukui, Shoichi  |e verfasserin  |4 aut 
700 1 |a Endo, Yushiro  |e verfasserin  |4 aut 
700 1 |a Shimizu, Toshimasa  |e verfasserin  |4 aut 
700 1 |a Kawakami, Atsushi  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 215(2020) vom: 15. Juni, Seite 108451  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:215  |g year:2020  |g day:15  |g month:06  |g pages:108451 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2020.108451  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 215  |j 2020  |b 15  |c 06  |h 108451